Antiviral treatment of chronic hepatitis C: advances and new challenges

Автор: Ubeeva Elena A., Botoeva Elena A., Ubeeva Iraida P., Nikolaev Sergey M.

Журнал: Вестник Бурятского государственного университета. Медицина и фармация @vestnik-bsu-medicine-pharmacy

Статья в выпуске: 3-4, 2018 года.

Бесплатный доступ

HCV infection is a major cause of chronic liver disease of chronically infected individuals. Today chronic hepatitis C is viewed at as a treatable condition due to significant changes in understanding of HCV pathogenesis and viral life cycle, advances in diagnosis and treatment. Use of direct-acting antiviral drugs (DAA) allows use of shortened treatment regimens with better safety profile and very few contraindications to treatment. However, despite prominent success of DAA questions of efficiency, safety, availability and drug resistance are still acute.

Glecaprevir, pibrentasvir, sofosbuvir, antiviral, daa, pangenotypic daa, drug resistance

Короткий адрес: https://sciup.org/148317811

IDR: 148317811

Статья научная